RE:RE:RE:RE:RE:RE:RE:Thank youPaul said he is going to accelerate the process even so Jim doesn't agreed with me what I heard was he described the dosing and early data as upcoming milestones so my take is they will announce any progress as soon as possible now exactly when nobody knows not even the company but I am pretty sure they are eager to announce early news.
As per holes for NASH we can speculate the size of them and how much the valuation should be discounted but not to allocate any NPV to a phase 3 trial is not the way market values other R&D companies.
The problem is not the hole of the trial the problem is the massive hole in their marketing of the trial.